Gsa Capital Partners LLP Cara Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$0.52 - $1.05 $93,544 - $188,888	-179,894 Reduced 79.9%	45,268 $41,000
Q4 2023 Feb 16, 2024	BUY	$0.6 - $1.65 $135,097 - $371,517	225,162 New	225,162 $166,000
Q2 2023 Aug 14, 2023	BUY	$2.83 - $4.94 $167,405 - $292,220	59,154 Added 262.51%	81,688 $231,000
Q1 2023 May 12, 2023	BUY	$4.89 - $12.27 $110,191 - $276,492	22,534 New	22,534 $110,000
Q2 2022 Aug 09, 2022	BUY	$7.45 - $13.84 $804,369 - $1.49 Million	107,969 Added 859.35%	120,533 $1.1 Million
Q1 2022 May 11, 2022	BUY	$9.94 - $12.65 $124,886 - $158,934	12,564 New	12,564 $153,000
Q4 2019 Feb 12, 2020	SELL	$16.11 - $25.98 $274,643 - $442,907	-17,048 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$18.28 - $26.91 $311,637 - $458,761	17,048 New	17,048 $312,000

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $15M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.